A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
Public ClinicalTrials.gov record NCT03551782. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter, Phase 1b Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination With Apalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety of the combination of cetrelimab, with apalutamide and to define a population of participants with metastatic castration-resistant prostate cancer (mCRPC) who respond to treatment with the combination of cetrelimab and apalutamide.
Study identification
- NCT ID
- NCT03551782
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 28, 2018 (Actual)
- Primary completion
- Nov 11, 2021 (Actual)
- Completion
- Nov 11, 2021 (Actual)
- Last update posted
- Feb 25, 2022
2018 – 2021
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco (UCSF) - Prostate Cancer Center | San Francisco | California | 94158-2350 | — |
| Regional Urology LLC | Shreveport | Louisiana | 71106 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109-5000 | — |
| Washington University | Bay Saint Louis | Mississippi | 63110 | — |
| New York University Langone Medical Center | New York | New York | 10016 | — |
| Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg | New York | New York | 10029-6542 | — |
| Levine Cancer Institute, Carolinas HealthCare System | Charlotte | North Carolina | 28204 | — |
| Centers for Advanced Urology, LLC; d/b/a MidLantic Urology | Bala-Cynwyd | Pennsylvania | 19004 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| University of Texas, MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03551782, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 25, 2022 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03551782 live on ClinicalTrials.gov.